Key points are not available for this paper at this time.
Dupilumab was highly effective in treating most children with moderate-to-severe AD with good safety outcomes in the real world. However, 10% of children may need alternative therapy because of drug ineffectiveness or side-effects.
Hosseini-Ashrafi et al. (Thu,) studied this question.